Drug Guidance for Subsidy 16/09/2025 Toripalimab for first-line systemic treatment of recurrent or metastatic nasopharyngeal carcinoma NRThe Ministry of Health’s Drug Advisory Committee has not recommended toripalimab in combinat... See all × 16/09/2025 Toripalimab for first-line systemic treatment of recurrent or metastatic nasopharyngeal carcinoma NRThe Ministry of Health’s Drug Advisory Committee has not recommended toripalimab in combination with chemotherapy for inclusion on the MOH List of Subsidised Drugs for first-line systemic treatment of recurrent or metastatic nasopharyngeal carcinoma. The decision was based on the unfavourable cost-effectiveness of toripalimab plus chemotherapy compared with chemotherapy alone, and the unacceptable price-volume agreement proposed by the company. Clinical indication, subsidy class and MediShield Life claim limit for toripalimab plus chemotherapy are provided in the Annex.
Post Marketing Information PMG 26/03/2025 Medication Guide LOQTORZI (lok tor zee) (toripalimab) injection
INTRAVENOUS Select a brand starting with the letter: L LOQTORZI CONCENTRATE FOR SOLUTION FOR INFUSION 240MG/6ML [SIN17212P]